Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Brings Halaven To India With A Tiered-Pricing Strategy

This article was originally published in PharmAsia News

Executive Summary

The Japanese drug firm is making a strong bid to make expensive drugs affordable in emerging markets like India. For those who cannot pay, the drug will be made available free of charge.

Advertisement

Related Content

How Eisai Hopes To Expand In India
In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC082921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel